IL198927A0 - Imidazopyridine inhibitors of iap - Google Patents

Imidazopyridine inhibitors of iap

Info

Publication number
IL198927A0
IL198927A0 IL198927A IL19892709A IL198927A0 IL 198927 A0 IL198927 A0 IL 198927A0 IL 198927 A IL198927 A IL 198927A IL 19892709 A IL19892709 A IL 19892709A IL 198927 A0 IL198927 A0 IL 198927A0
Authority
IL
Israel
Prior art keywords
imidazopyridine
iap
inhibitors
imidazopyridine inhibitors
Prior art date
Application number
IL198927A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL198927A0 publication Critical patent/IL198927A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL198927A 2006-12-19 2009-05-25 Imidazopyridine inhibitors of iap IL198927A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87082106P 2006-12-19 2006-12-19
PCT/US2007/087532 WO2008079735A1 (en) 2006-12-19 2007-12-14 Imidazopyridine inhibitors of iap

Publications (1)

Publication Number Publication Date
IL198927A0 true IL198927A0 (en) 2010-02-17

Family

ID=39361343

Family Applications (1)

Application Number Title Priority Date Filing Date
IL198927A IL198927A0 (en) 2006-12-19 2009-05-25 Imidazopyridine inhibitors of iap

Country Status (12)

Country Link
US (2) US8063218B2 (enExample)
EP (1) EP2125809A1 (enExample)
JP (1) JP2010513561A (enExample)
KR (1) KR20090094461A (enExample)
CN (1) CN101605786A (enExample)
AU (1) AU2007337104A1 (enExample)
BR (1) BRPI0719481A2 (enExample)
CA (1) CA2671607A1 (enExample)
IL (1) IL198927A0 (enExample)
NZ (1) NZ577150A (enExample)
RU (1) RU2466131C2 (enExample)
WO (1) WO2008079735A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773766B1 (en) * 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
BRPI0607988A2 (pt) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals composto, composição farmacêutica, e método para induzir apoptose em uma célula
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
JP2009512719A (ja) 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Ｉａｐｂｉｒドメイン結合化合物
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
AR063943A1 (es) * 2006-07-24 2009-03-04 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer.
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CN101687787A (zh) * 2007-04-30 2010-03-31 健泰科生物技术公司 Iap的抑制剂
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
KR20100110870A (ko) * 2008-01-11 2010-10-13 제넨테크, 인크. Ｉａｐ의 억제제
NZ590550A (en) * 2008-08-02 2013-05-31 Genentech Inc Inhibitors of Apoptosis (IAP) for treating cancer
US20110218211A1 (en) * 2008-08-16 2011-09-08 Genentech, Inc. Azaindole inhibitors of iap
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
TW201109335A (en) 2009-08-04 2011-03-16 Takeda Pharmaceutical Heterocyclic compounds
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2534170B1 (en) 2010-02-12 2017-04-19 Pharmascience Inc. Iap bir domain binding compounds
PL2611797T3 (pl) * 2010-08-31 2017-05-31 Hanmi Science Co., Ltd. Pochodne chinoliny lub chinazoliny o aktywności wywoływania apoptozy wobec komórek
KR20140011773A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 이중 저해 활성을 갖는 헤테로고리 유도체
WO2019091492A1 (zh) * 2017-11-13 2019-05-16 南京明德新药研发股份有限公司 用作iap抑制剂的smac模拟物及其用途
JP7515175B2 (ja) 2018-07-31 2024-07-12 ファイメクス株式会社 複素環化合物
AU2020233068B2 (en) * 2019-03-07 2025-04-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination of IAP inhibitor and immune checkpoint inhibitor
EP3967702B1 (en) * 2019-05-10 2024-03-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystallization of smac mimic used as iap inhibitor and preparation method thereof
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
FR2575753B1 (fr) 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3685626T2 (de) 1985-09-26 1993-01-28 Beckmann Research Inst Of The Sequenzierung von peptiden.
US4935494A (en) 1988-11-15 1990-06-19 City Of Hope C-terminal peptide and protein sequencing
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
RU2139731C1 (ru) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US5559209A (en) 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6472172B1 (en) 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
EP1315811A2 (en) 2000-08-24 2003-06-04 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
US6992063B2 (en) 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
AU2002253908A1 (en) 2001-02-08 2003-02-17 Thomas Jefferson University A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
MXPA03010762A (es) 2001-05-31 2005-03-07 Univ Princeton Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap.
US20030157522A1 (en) 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
CA2491041A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ES2318167T3 (es) 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
WO2004017991A1 (en) 2002-08-13 2004-03-04 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas
AU2003216203A1 (en) 2003-02-07 2004-09-06 Genentech, Inc. Compositions and methods for enhancing apoptosis
US20040171554A1 (en) 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
IL156263A0 (en) 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
SE0301904D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
US7067274B2 (en) 2003-11-13 2006-06-27 Genentech, Inc. Compositions and methods for the screening pro-apoptotic compounds
CA2582734C (en) 2004-03-01 2011-05-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
EP2253614B1 (en) * 2004-04-07 2012-09-19 Novartis AG Inhibitors of IAP
MXPA06014969A (es) 2004-07-02 2007-02-08 Genentech Inc Inhibidores de iap.
EP1773766B1 (en) 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) * 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
CN1808446A (zh) * 2005-01-22 2006-07-26 鸿富锦精密工业（深圳）有限公司 高速电路中耦合传输线等效模型的撷取方法
BRPI0607988A2 (pt) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals composto, composição farmacêutica, e método para induzir apoptose em uma célula
CN101374829A (zh) * 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
PE20110224A1 (es) * 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
RU2009117701A (ru) * 2006-10-12 2010-11-20 Новартис АГ (CH) Производные пирролидина в качестве ингибиторов iap

Also Published As

Publication number Publication date
RU2009127800A (ru) 2011-01-27
US20120015974A1 (en) 2012-01-19
CA2671607A1 (en) 2008-07-03
KR20090094461A (ko) 2009-09-07
NZ577150A (en) 2012-04-27
BRPI0719481A2 (pt) 2014-02-11
AU2007337104A1 (en) 2008-07-03
CN101605786A (zh) 2009-12-16
EP2125809A1 (en) 2009-12-02
RU2466131C2 (ru) 2012-11-10
US20100130539A1 (en) 2010-05-27
JP2010513561A (ja) 2010-04-30
US8063218B2 (en) 2011-11-22
WO2008079735A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
IL198927A0 (en) Imidazopyridine inhibitors of iap
ZA200906946B (en) Inhibitors of iap
IL195031A0 (en) Uses of dpp-iv inhibitors
IL191997A0 (en) Inhibitors of iap
EP2318395A4 (en) IPA INHIBITORS
IL195010A0 (en) Bicyclic derivatives as cetp inhibitors
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
IL178104A0 (en) Inhibitors of iap
IL179854A0 (en) Inhibitors of iap
IL195792A0 (en) Amino-piperidine derivatives as cetp inhibitors
SI2383271T1 (sl) Aminokinoloni kot inhibitorji gsk-3
EP2318401A4 (en) AZAINDOLI INHIBITORS OF IPA
ZA201005618B (en) Iap inhibitors
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
ZA200902640B (en) Purines as PKC-Theta inhibitors
GB0621607D0 (en) Inhibitors of c-Met
ZA201101909B (en) Iap inhibitors
ZA201004765B (en) Inhibitors of iap
GB0622084D0 (en) Inhibitors of HSP90
ZA200810008B (en) Amino-piperidine derivatives as CETP inhibitors
GB0621107D0 (en) Inhibitors of phosphodiesterase-4
AU2013248173A1 (en) Inhibitors of IAP
HK1140757A (en) Inhibitors of iap
GB0622367D0 (en) Phosphodiesterase inhibitors
AP2009004815A0 (en) Inhibitors of phosphodiesterase type-IV